RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ascendis Pharma A/S Stock

Ascendis Pharma A/S Liabilities 2024

Ascendis Pharma A/S Liabilities

971.28 M EUR

Ticker

ASND

ISIN

US04351P1012

WKN

A14M6X

In 2024, Ascendis Pharma A/S's total liabilities amounted to 971.28 M EUR, a 17.53% difference from the 826.4 M EUR total liabilities in the previous year.

Ascendis Pharma A/S Aktienanalyse

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone. Ascendis Pharma A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Ascendis Pharma A/S's Liabilities

Ascendis Pharma A/S's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Ascendis Pharma A/S's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Ascendis Pharma A/S's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Ascendis Pharma A/S's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Ascendis Pharma A/S’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Ascendis Pharma A/S stock

What is the level of liabilities of Ascendis Pharma A/S this year?

Ascendis Pharma A/S has a debt balance of 971.28 M EUR this year.

What were the liabilities of Ascendis Pharma A/S compared to the previous year?

The liabilities of Ascendis Pharma A/S have increased by 17.53% increased compared to the previous year.

What are the consequences of high debt for investors of Ascendis Pharma A/S?

High liabilities can pose a risk for investors of Ascendis Pharma A/S, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Ascendis Pharma A/S?

Low liabilities mean that Ascendis Pharma A/S has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Ascendis Pharma A/S affect the company?

An increase in liabilities of Ascendis Pharma A/S can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Ascendis Pharma A/S affect the company?

A decrease in the liabilities of Ascendis Pharma A/S can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Ascendis Pharma A/S?

Some factors that can influence the liabilities of Ascendis Pharma A/S include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Ascendis Pharma A/S so important for investors?

The liabilities of Ascendis Pharma A/S are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Ascendis Pharma A/S take to modify the liabilities?

To change its liabilities, Ascendis Pharma A/S can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Ascendis Pharma A/S pay?

Over the past 12 months, Ascendis Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ascendis Pharma A/S is expected to pay a dividend of 0 EUR.

What is the dividend yield of Ascendis Pharma A/S?

The current dividend yield of Ascendis Pharma A/S is .

When does Ascendis Pharma A/S pay dividends?

Ascendis Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ascendis Pharma A/S?

Ascendis Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Ascendis Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ascendis Pharma A/S located?

Ascendis Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ascendis Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ascendis Pharma A/S from 7/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/26/2024.

When did Ascendis Pharma A/S pay the last dividend?

The last dividend was paid out on 7/26/2024.

What was the dividend of Ascendis Pharma A/S in the year 2023?

In the year 2023, Ascendis Pharma A/S distributed 0 EUR as dividends.

In which currency does Ascendis Pharma A/S pay out the dividend?

The dividends of Ascendis Pharma A/S are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Ascendis Pharma A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Ascendis Pharma A/S

Our stock analysis for Ascendis Pharma A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ascendis Pharma A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.